

A DECLARATION OF JOINT WORKING BETWEEN WATERSIDE HEALTH PRIMARY CARE NETWORK AND
ASTRAZENECA UK LTD

Waterside Health PCN and AstraZeneca Ltd are engaged in a Joint Working Project entitled, Heart Failure Service Collaboration using Oberoi Consulting disease management tool and clinical resource

The aim and objectives of this project are:

- Ensure patients living with HFrEF are identified and accurately coded for HFrEF within QoF.
- Deliver Heart Failure Nurse review for prevalent population of patients eligible for SMR optimisation
- Reduce unplanned admissions for HF. Ensure treatment is appropriately optimised and aligned to local Plymouth Hospital Trust HF guidelines.
- Reduce variation of HFrEF prevalence within Waterside Health PCN and appropriate referrals to Secondary Care.
- Evidenced based Medicines Optimisation.

The project will run from June 2022 – June 2023. Both parties have contributed resources to the initiative.

Through the project it is anticipated that there will be a triple win for the NHS, Patients and AstraZeneca, these will be measured against baseline (where metrics are available ie QoF, patient records)

NHS: Improved disease registers, proactive case finding, evidence supported review, stratification of highest risk patients, reduced hospital admissions

Patients: Proactive disease management, quicker access to contemporary medicines, improved QOL and better disease prognosis.

AZ: Increased reputation in partnership with NHS, expanded patient access to NICE Technology appraised Dapagliflozin